Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
TERBINAFINE HYDROCHLORIDE
Medimpex France SA
250 Milligram
Tablets
2006-07-28
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Terbinafine 250 mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 250 mg terbinafine (as hydrochloride). For list of excipients see section 6.1 3 PHARMACEUTICAL FORM Tablet. White, or almost white, round, biconvex tablets with a breakline on one side and 250 engraved on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS 1. Treatment of Terbinafine sensitive fungal infections such as _Tinea corporis_, _Tinea cruris _and _Tinea pedis _(caused by Dematophytes, _see section 5.1,Pharmacodynamic properties_) is considered appropriate due to the site, severity or extent of the infection. 2. The treatment of onychomycosis (terbinafine-sensitive fungal infection of the nails) caused by dermatophytes. N.B. Orally administered terbinafine tablets are not effective against _Pityriasis versicolor._ Consideration should be given to official guidance on the appropriate use of antifungal agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ROUTE OF ADMINISTRATION: Oral use The duration of treatment is dependent on the indication and the degree of severity of the infection. Adults: 250mg once daily. Patients with impaired renal function (creatinine clearance less than 50ml/minute or serum creatinine of more than 300 micromol/l) should receive half the normal dose. Skin infections: The likely durations of treatment for _Tinea pedis_, _Tinea corporis _and _Tinea cruris _are 2 – 4 weeks. For _Tinea pedis _(interdigital, plantar/moccasin-type): recommended treatment periods may be up to 6 weeks. Complete disappearance of the symptoms of the infection may not occur until several weeks after mycological cure. IRISH MEDICINES BOARD ______________________________________________________________________________________ Read the complete document